ACNP
52nd Annual Meeting
Preliminary Program

December 8-12, 2013
The Westin Diplomat Resort & Spa
Hollywood, Florida

President: David A. Lewis, M.D.
Program Committee Chair: Randy D. Blakely, Ph.D.
Program Committee Co-Chair: Pat R. Levitt, Ph.D.

This meeting is jointly sponsored by the Vanderbilt University School of Medicine Department of Psychiatry and the American College of Neuropsychopharmacology.
SCHEDULE

**Friday, December 6, 2013**

11:00 am – 5:00 pm  SOBP Council Meeting

**Saturday, December 7, 2013**

8:00 am - 3:00 pm  Council Meeting
8:00 am - 5:00 pm  Membership Committee Meeting
9:00 am - 7:00 pm  Registration
2:00 pm – 4:00 pm  NPP & NPPR Editors Meeting
4:00 pm – 5:30 pm  Publications Committee Meeting
4:00 pm – 5:30 pm  Ethics Committee Meeting
5:30 pm – 6:30 pm  ACNP Website Editors Meeting
6:30 pm – 8:30 pm  Travel Award Reception *(by invitation)*

**Sunday, December 8, 2013**

7:00 am - 7:00 pm  Registration
8:30 am - 11:30 am  Neuropsychopharmacology Reviews Plenary: “*Frontiers in Discovery and Neurotherapeutics*”
11:30 am – 1:00 pm  Past President’s Luncheon
11:30 am – 1:00 pm  Lunch
11:30 am – 1:00 pm  Program Committee Meeting
11:30 am – 1:00 pm  Liaison Committee Meeting
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 am – 1:00 pm</td>
<td><strong>NPP Editorial Board Meeting</strong> <em>(by invitation)</em></td>
</tr>
<tr>
<td>1:00 pm – 2:30 pm</td>
<td><strong>Q&amp;A Forum with NIH Institutes Directors</strong></td>
</tr>
<tr>
<td>2:30 pm – 6:30 pm</td>
<td><strong>Paper Sessions: “Hot Topics”</strong></td>
</tr>
<tr>
<td>7:00 pm – 9:00 pm</td>
<td><strong>Opening Reception</strong></td>
</tr>
</tbody>
</table>

**Monday, December 9, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 am – 8:00 am</td>
<td><strong>CDI Booster Session</strong></td>
</tr>
<tr>
<td>7:00 am - 6:00 pm</td>
<td><strong>Registration</strong></td>
</tr>
<tr>
<td>8:00 am - 11:30 am</td>
<td><strong>President’s Plenary: “Neural Circuitry Structure and Plasticity: Substrate for Brain Disorders and Novel Therapeutics”</strong></td>
</tr>
<tr>
<td></td>
<td>Gina Turrigiano, Ph.D., <em>Homeostatic Plasticity: Keeping your Brain in Balance</em></td>
</tr>
<tr>
<td></td>
<td>Z. Josh Huang, Ph.D., <em>Genetic Dissection of GABAergic Circuits in Neocortex: Chandeliers Light up the Path</em></td>
</tr>
<tr>
<td></td>
<td>Carla Shatz, Ph.D., <em>Surprise at the Synapse: MHC Class I, Pruning and Plasticity</em></td>
</tr>
<tr>
<td></td>
<td>Amy Arnsten, Ph.D., <em>Dynamic Modulation of Dorsolateral Prefrontal Cortex Microcircuits: Focus of Vulnerability in Mental Disease</em></td>
</tr>
<tr>
<td>10:30 am - 4:30 pm</td>
<td><strong>Poster Viewing</strong></td>
</tr>
<tr>
<td>11:30 am - 1:30 pm</td>
<td><strong>Lunch</strong></td>
</tr>
<tr>
<td>11:30 am - 1:00 pm</td>
<td><strong>Women’s Luncheon</strong> <em>(reservations requested)</em></td>
</tr>
<tr>
<td></td>
<td>Guest Speaker: TBD</td>
</tr>
<tr>
<td>1:30 pm – 3:00 pm</td>
<td><strong>Distinguished Lecture – Huda Y. Zoghbi, M.D.</strong></td>
</tr>
<tr>
<td></td>
<td><em>The Story of Rett Syndrome and the insight it provides into Neuropsychiatric Disorders</em></td>
</tr>
<tr>
<td>3:00 pm - 5:30 pm</td>
<td><strong>Mini-Panel Sessions</strong></td>
</tr>
</tbody>
</table>
Session 1
Neuronal Immaturity in Schizophrenia
Chair: Mickey Matsumoto

- **GABA Signaling in Postmortem Human Brain and Schizophrenia: A Question of Immaturity?**
  Speaker: Joel Kleinman

- **Immature Neurons in Schizophrenia? Support from Investigations on Proteoglycan Expression**
  Speaker: Sabina Berretta

- **Immature Dentate Gyrus as a Candidate Endophenotype of Neuropsychiatric Disorders**
  Speaker: Tsuyoshi Miyakawa

Session 2
Social Processes Initiative in Neurobiology of the Schizophrenia(s)
Chair: Anil Malhotra

- **The Neural Circuitry of Social Impairments in Schizophrenia Spectrum Disorders**
  - Robert Buchanan

- **Altered Structural and Functional Network Topology in Deficit Schizophrenia**
  - Philip Szeszko

- **Network Topology in Deficit Schizophrenia, Nondeficit Schizophrenia, and Bipolar Disorder: From Circuits to Functional Outcome**
  - Aristotle Voineskos

3:00 pm - 5:30 pm Panel Sessions

Session 1
Kicking Over the Traces - Noncatecholic Biogenic Amines and Their Receptors
Chair: David Grandy

- **Evidence from Molecular Modeling, Site-Directed Mutagenesis and Behavioral Testing Indicate Trace Amine-Associated Receptor 1 is a Methamphetamine Receptor**
  - David Grandy

- **Selective TAAR1 Ligands and Transgenic Animal Models Reveal a Role of TAAR1 in Cognitive, Neurologic and Psychiatric Disorders**
  - Raul Gainetdinov

- **Trace Amine Associated Receptor 1 Modulation of the Rewarding and Immunological Effects of Drugs of Abuse Supports its Relevance as a Therapeutic Target**
  - Gregory Miller

- **The Activation of Intracellular Signaling Systems by Amphetamines: A Potential Role for Trace Amine Receptors**
  - Susan Amara

- Discussant: David Shurtleff
Session 2
Autism Spectrum Disorders: From Rare Chromosomal Abnormalities to Common Molecular Targets
Chair: Ted Abel
- Role of copy number variants in autism spectrum disorders
  o Santhosh Girirajan
- Comprehensive phenotyping of mouse autism models
  o Ted Abel
- Tbx1 and Sept5 contribute to behavioral and neuronal phenotypes in mouse models of 22q11.2-associated ASD
  o Noboru Hiroi
- The Translation of Translational Control in Autism Spectrum Disorders
  o Eric Klann
- Discussant: Alice Luo Clayton

Session 3
Circuitry Underlying Obsessive-compulsive Disorder: Lessons from Deep Brain Stimulation and Ablative Surgery
Chair: Suzanne Haber
- Ablative Limbic System Surgery for the Treatment of OCD
  o Emad Eskandar
- The circuitry of deep brain stimulation and cingulotomy: monkey tracing vs. human tracking
  o Suzanne Haber
- DBS of ventral striatum in rodents modulates fear extinction via prefrontal and orbitofrontal projections
  o Gregory Quirk
- Deep Brain Stimulation for Intractable OCD: Population and Outcomes
  o Benjamin Greenberg
- Discussant: Scott Rauch

Session 4
The Role of Inflammation in the Pathophysiology of Mood, Aggressive and Medical Disorders: a Deadly Combination
Chair: Emil Coccaro
- Plasma Markers of Inflammation are Elevated in Subjects with Intermittent Explosive Disorder and Correlate Directly with Aggression in Human Subjects
  o Emil Coccaro
- Stress, Trauma, and Inflammation in Non-Psychiatric Subjects
  o Janice Kiecolt-Glaser
- Inflammation and Depression: Sleep Disturbance Moderates Induction of Depressed Mood by an Inflammatory Challenge
  o Michael Irwin
• Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients with Treatment-Resistant Depression
  o Jennifer Felger
• Discussant: Charles B. Nemeroff

Session 5
Can Biology Inform Treatment Prediction and Selection in Depression?
Chair: Amit Etkin
• Large-scale Pre-treatment Prediction of Remission with Antidepressants for Individual Patients Based on Cognitive and Emotional Test Performance, as well as Its Neuroimaging Correlates
  o Amit Etkin
• Initial Results of the NIMH-funded EMBARC Study
  o Madhukar Trivedi
• Inflammatory Biomarkers Predict Differential Outcome of Depression Treatment with Escitalopram and Nortriptyline in the GENDEP Project
  o Rudolf Uher
• Brain Serotonin 1A Receptor Binding as a Predictor of Treatment Outcome in Major Depressive Disorder
  o Ramin Parsey
• Discussant: Thomas R. Insel

Session 6
Structural and Functional Brain Changes in Young People at Risk for Severe Mental Illness
Chair: Martin Alda
• Clinical Stages and Developmental Trajectories of Bipolar Disorder: Family-based Analysis
  o Martin Alda
• Population Neuroscience and Psychiatric Genetics: A Two-way Street
  o Tomas Paus
• Vulnerability or Resilience? Brain Developmental Studies in Non Psychotic Siblings of Childhood Onset Schizophrenia Patients
  o Nitin Gogtay
• Neuroanatomical Changes in Bipolar Disorders - Causes Versus Consequences of the Illness
  o Tomas Hajek
• Discussant: Mary L. Phillips

5:30 pm - 7:30 pm   Poster Session I with Reception
7:30 pm - 9:00 pm   Issue Oriented Study Groups
Session 1
The Challenges of Designing and Interpreting Clinical Trials with Depot Antipsychotics
Chair: W. Wolfgang Fleischhacker
Raymond Sanchez
Srihari Gopal
Maxine Patel
Stephan Heres
Keith Nuechterlein
Hiroyuki Uchida

Session 2
Mental Illness, Violence and the Gun Control Debate: Evidence, Policy, Privacy and Stigma - on Behalf of the ACNP Ethics Committee
Chair: David Pickar
Co-Chair: Jerrold Rosenbaum
David Pickar
Jerrold Rosenbaum
Emil Coccaro
Kenneth Davis
Paul Appelbaum
Brian Frosh
J. Dee Higley

Session 3
New Models of Open Innovation to Rejuvenate the Biopharmaceutical Ecosystem, A Proposal by the ACNP Liaison Committee
Chair: Dean Wong
Co-Chair: Lisa Gold
Dean Wong
Robert Innis
Lawrence Sung
Steven Paul
Phillip Phan
Steven Grant
Husseini Manji

Session 4
The Assessment Of Suicidal Ideation, Behavior & Risk: At Baseline; As a Measure of Clinical Outcome, and/or as a Treatment Emergent SAE
Chair: Roger Meyer
Co-Chair: Eric Youngstrom
Ahmad Hameed
John Greist
Phillip Chappell
J. John Mann
David Sheehan
Cheryl McCullumsmith
Session 5
Medical and Non-Medical Use of Stimulant Drugs for Cognitive Enhancement
Chair: James Swanson
William Pelham
Trevor Robbins
Barbara Sahakian
James McCracken
Susanna Visser
Ruben Baler
Kathleen Merikangas
Raul Gonzalez
James Waxmonsky
Tim Wigal
Marc Lerner
Wilson Compton

Tuesday, December 10, 2012

6:45 am – 8:00 am  CDI Booster Session
7:00 am – 6:00 pm  Registration
7:30 am – 8:30 am  ACNP Leadership & Institute Directors
7:00 am – 8:30 am  Education & Training Committee Meeting
7:00 am – 8:30 am  Membership Advisory Task Force Meeting
8:30 am – 11:00 am  Mini-Panel Sessions

Session 1
Biochemical and Behavioral Pharmacology of Synthetic Cathinone Derivatives Found in Psychoactive Bath Salts Products
Chair: Richard Rothman

- **Effects of newly-emerging synthetic cathinone derivatives on monoamine transporter function in rats**
  - Michael Baumann
- **Intravenous self-administration of 3,4-methylenedioxypyrovalerone (MDPV) and 4-methylmethcathinone (4-MMC, mephedrone) in rats**
  - Michael Taffe
- Abuse-related and abuse-limiting effects of synthetic cathinone derivatives on intracranial self-stimulation in rats
  - Matthew Banks

Session 2
After the Trauma: Developmental Trajectories from Childhood to Adult Psychiatric Disorders
Chair: Michael De Bellis
- The Neurobiology of PTSD Symptoms in Maltreated Children and Adolescents
  - Michael De Bellis
- Sex-specific Effects of Childhood Emotional Abuse on Affective Processing in Bipolar Disorder Patients
  - Katherine Burdick
- The Long-Term Consequences of Childhood Maltreatment: Effects on Brain Structure and Subclinical Psychopathology in Healthy Adults
  - Pamela DeRosse

8:30 am – 11:00 am  Panel Sessions

Session 1
Augmentation of Antidepressant Response by Autoreceptor-Mediated Mechanisms: Clinical Experience and Mechanisms of Action
Chair: Salomon Langer
- Autoreceptor-mediated Regulation of Neurotransmission: Pharmacological Targets and Potential for Improved Treatment of Major Psychiatric Disorders
  - Salomon Langer
- Rapid Augmentation of Antidepressant Effect in Treatment-resistant MDD by Add-on Low Dose Aripiprazole
  - Daniel Casey
- Low Doses of Atypical Antipsychotic Drugs Added to Selective Serotonin Inhibitors Produce a Ketamine-like Facilitation of Prefrontal Glutamatergic Neurotransmission
  - Torgny Svensson
- Emerging Role of Atypical Antipsychotics as Add-on Therapy in Major Depression
  - Speaker Siegfried Kasper
- Discussant: Dennis S. Charney

Session 2
Neuroactive Steroids and Oxysterols as Endogenous Modulators of GABA and Glutamate Receptors: Basic Mechanisms and Therapeutic Implications
Chair: Steven Paul
- GABAergic Neurosteroids as Novel Targets for Therapeutic Drug Development in Psychiatry
  - Charles Zorumski
- Natural and Synthetic Neuroactive Steroids and Oxysterols as Potent NMDA Receptor Allosteric Modulators: Therapeutic Considerations
  - Steven Paul
- Neuroactive Steroids Ganaxolone and Allopregnanolone in the Treatment of Epilepsy, Traumatic Brain Injury, and Neurobehavioral Disorders
Session 3
The Future of Translational Research in Addiction
Chair: Harriet de Wit
- Cross-species Behavioral Tests for Investigations of Addictive and Psychiatric Disorders
  - Mark Geyer
- Neurocircuitries for Social Stress and Drug Abuse: Novel Targets for Intervention
  - Klaus Miczek
- Towards consilience in animal and human behavioural models in addiction
  - David Stephens
- Identifying the molecular determinants of inhibitory control problems in addictions
  - J. David Jentsch
- Discussant: Harriet de Wit

Session 4
At the Crossroads of Physics, Physiology, and Psychiatry: Rational Design of Noninvasive Neuromodulation Therapies
Chair: Sarah Lisanby
- Targeting of Transcranial Direct Current Stimulation: Insights from Cellular and Computational Models
  - Marom Bikson
- Optimizing Stimulus Pulse Characteristics for Transcranial Magnetic Stimulation and Electroconvulsive Therapy Via Device Development, Computational Modeling, and Biophysically-motivated Dosing Paradigms
  - Angel Peterev
- Mechanisms of Targeting Cortical State Dynamics with Neuromodulation
  - Flavio Frohlich
- Enhancement of Working Memory in Sleep Deprived Young Adults and in Elderly Adults using rTMS Informed by Covariance-modeled fMRI
  - Bruce Luber
- Discussant: Zafiris J. Daskalakis

Session 5
Nutrition, Neurodevelopment, and Risk for Schizophrenia and Autism: From Epidemiology to Epigenetics
Chair: Joshua Roffman
- Periconceptional folic acid and neurodevelopmental disorders: historical context and current research
  - Ezra Susser
- Effects of Periconceptional Folate on Language Delay and Autism Spectrum Disorders: The Norwegian Mother and Child Cohort Study
  - Camilla Stoltenberg
• **Longitudinal Effects of In Utero Folate Exposure on Cortical Thickness: Implications for Neurodevelopmental Disorders**
  o Joshua Roffman
• **The placental and neuronal methylomes at the interface of genetic and environmental risk and protective factors in autism**
  o Janine LaSalle
• Discussant: Donald Goff

### Session 6
**Peripheral Immune and Endocrine Pathways as Markers of PTSD Risk and Symptom Development: Evidence from Prospective Studies**
Chair: Victoria Risbrough
• **Longitudinal Plasma Testosterone Trajectory and its Relation to Combat, Temperament and PTSD**
  o Eric Vermetten
• **Evidence for Plasma C-Reactive Protein Concentration as Biomarker of PTSD Risk**
  o Dewleen Baker
• **Blood-Based Gene-Expression Predictors of PTSD Risk and Resilience among Deployed Marines: A Pilot Study**
  o Stephen Glatt
• **Exaggerated Threat Sensitivity and Avoidance as Contributors to Elevated Inflammation in Posttraumatic Stress Disorder: Data from the Mind Your Heart Study**
  o Aoife O’Donovan
• Discussant: Thomas Neylan

10:30 am - 4:30 pm  **Poster Viewing**
11:00 am – 12:30 pm  **Lunch**
11:00 am – 12:30 pm  **Public Information Committee Meeting**
11:00 am – 12:30 pm  **ACNP Corporate Liaison Luncheon (by invitation)**
11:30 am – 12:30 pm  **SOBP Biological Psychiatry Journal Editors Meeting**
11:30 am – 1:30 pm  **Data Blitz**
1:30 pm – 3:00 pm  **Career Development Session**
3:00 pm - 5:30 pm  **Mini-Panel Sessions**

### Session 1
**Emerging Role of the Primary Cilium in Neuropsychiatric Disorders**
Chair: Bernard Lerer
• **The Role of AHI1 in Regulating Primary Cilia Signaling**
  o Russell Ferland
• **Functional Significance of Primary Cilia to GPCR Signaling and Relationship to Neuropsychiatric Disease**
• Mark Von Zastrow
  • Abnormal Response to Stress in Heterozygous AHI1 Knockout Mice: A Consequence of Primary Ciliary Dysfunction?
    • Bernard Lerer

Session 2
Adolescent Brain Development and Affective Disorders: The Role of Reward and Threat Circuitry
Chair: Erika Forbes
  • Adolescent VTA Neurons Exhibit Latent Neuronal Correlate of Reward Opportunity
    • Bita Moghaddam
  • Adolescents’ Neural Response to Personally Relevant Social Reward Is Associated with Severity of Mania and Depression
    • Erika Forbes
  • Parallel Processing Brain Networks Illustrating Dynamic Interplay Between Emotional and Cognitive Operations in Developing Youth with Affective Disorder
    • Ellen Leibenluft

3:00 pm - 5:30 pm Panel Sessions

Session 1
Treating Addiction: Should We Aim High or Low?
Chair: Marina Wolf
  • Rapid LTP in accumbens is a common feature of relapse to multiple classes of addictive drug
    • Peter Kalivas
  • Synaptic Depression via Positive Allosteric Modulation of mGluR1 Suppresses Cue-induced Cocaine Craving
    • Marina Wolf
  • Silent Synapse-based Circuitry Reorganization in Cocaine Craving
    • Yan Dong
  • Withdrawal from Acute Amphetamine Potently Down-Regulates VTA Dopamine Neuron Activity: Reversal by Ketamine
    • Anthony Grace
  • Discussant: Anissa Abi-Dargham

Session 2
Anxiety and the Striatum, an Unusual Suspect
Chair: Monique Ernst
  • Neural Response in Striatum Varies by Reward Magnitude, Decision Making, and Anxiety Diagnosis in Adolescents
    • Amanda Guyer
  • Cortico-amygdala Pathways form Hierarchical Networks that Predict Output to the Striatum
    • Julie Fudge
  • The Impact of Induced Anxiety on Ventral Striatal Response to Aversive and Appetitive Prediction Error Signals
Session 3
Posttraumatic Stress Disorder: From Markers to Mechanisms
Chair: Murray Stein
- Identification of Novel Gene Regulatory Networks Associated with PTSD: Evidence from Whole Genome Studies Examining DNA Methylation
  - Douglas Williamson
- Allele Specific Epigenetic Modifications - A Molecular Mediator of Gene - Environment Interactions in Stress Related Psychiatric Disorders?
  - Torsten Klengel
- Opioid Receptor-Like 1 (OPRL1) is Involved in Amygdala-dependent Fear in Mice and Humans with PTSD
  - Kerry Ressler
- Contextual Processing Deficits in PTSD: Translational Studies
  - Israel Liberzon
- Discussant: Charles R. Marmar

Session 4
Biotypes of Psychosis
Chair: Carol Tamminga
- Phenotypic characterization of the schizophrenia- bipolar disorder continuum.
  - Matcheri Keshavan
- Identification of distinct psychosis biotypes with multivariate taxometric analyses of neuro-pathologically relevant biomarkers
  - Brett Clementz
- Validating Psychosis Biotypes
  - Carol Tamminga
- Multivariate fusion methods identify gene components associated with heritable resting state fMRI abnormalities in BSNIP probands and relatives
  - Godfrey Pearlson
- Discussant: Steven Edward Hyman

Session 5
An Update from the Clinic on mGluR2/3 Approaches for Treating Schizophrenia – Understanding Human Circuit Engagement through to Recent Clinical Trials
Chair: Nicholas Brandon
- The Development of Pomaglumetad Methionil as an Innovative Glutamate-based Pharmacotherapy for Schizophrenia
  - Bruce Kinon
- Discovery and early clinical development of novel mGlu2 receptor PAMs
  - Hilde Lavreysen
- AZD8529 - an mGluR2 positive allosteric modulator for the treatment of schizophrenia
Alan Cross

- Efficacy of an mGluR2 agonist (LY354740) and an mGluR2 positive allosteric modulator (AZD8529) in attenuating ketamine effects in humans
  - John Krystal
- Discussant: Daniel R. Weinberger

**Session 6**

**Pathophysiology and Treatment of Obesity and Glucose Dysregulation in Schizophrenia**

Chair: L. Jarskog

- Effect of metformin on weight in patients with schizophrenia with impaired fasting glucose
  - Scott Stroup
- Dopamine, Clean Up Your “AKT!” Restoring Insulin Signaling in Brain
  - Aurielio Galli
- No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia
  - Xiaoduo Fan
- Dysglycemic Signals in Antipsychotic-Treated Children and Adolescents with Schizophrenia-Spectrum Disorders: Trajectories, and Moderating and Mediating Factors
  - Christoph Correll
- Discussant: Robert W. Buchanan

5:30 pm – 7:30 pm  Poster Session II with Reception

6:00 pm – 11:00 pm  Council Meeting with Committee Chair Reports

**Wednesday, December 11, 2013**

7:00 am - 8:00 am  ASCP Board of Directors Meeting

7:00 am  CDI Booster Session

7:30 am - 5:30 pm  Registration

8:30 am - 11:00 am  Mini-Panel Sessions

**Session 1**

*Are the Putative Therapeutic Effects of Kappa-opioid Antagonists Explained by Anti-stress Actions?*

Chair: William Carlezon

- Disruption of Kappa-opioid Receptor Actions Reduces Stress Effects on Cognitive Function and Anxiety-like Behavior
  - Ashlee Van’t Veer
• *Dynorphin-kappa Systems in Compulsive-like Responding with Extended Access to Elicit Drugs*
  o George Koob
• *The Dissociable Effects of Kappa-Opioid Receptor Activation on Intolerance to Delay and Response Inhibition*
  o Brendan Walker

**Session 2**

*Developing Imaging Biomarkers for Treatment Development: Beyond CNTRICS, CNTRaCs and NEWMEDS*

Chair: Cameron Carter

• *New Neuroscience Based Cognitive Paradigms for Biomarker Research in Schizophrenia*
  o Deanna Barch
• *Developing Imaging Biomarkers for Treatment Development: Beyond CNTRICS, CNTRaCs and NEWMEDS*
  o Angus MacDonald
• *Imaging biomarkers for psychiatric disorders: the NEWMEDS experience*
  o Andreas Meyer-Lindenberg

8:30 am - 11:00 am **Panel Sessions**

**Session 1**

*Manipulating BDNF-TrkB Signaling in Brain Disorders: Complex Regulation and Cellular & Systems Level Interactions as Novel Substrates for Translational Medicine*

Chair: Keri Martinovich

• *Differential Contribution of Individual BDNF Splice Variants to Brain and Behavioral Functions*
  o Keri Martinovich
• *Role of Slitrk5 in Regulating BDNF Dependent Signaling*
  o Francis Lee
• *Convergence of BDNF and Glucocorticoid Receptor Signaling*
  o Moses Chao
• *Synaptic Repair: Translating BDNF Biology into New Medicines for Psychiatric Diseases*
  o Bai Lu
• Discussant: Ronald S. Duman

**Session 2**

*The Ventromedial Prefrontal Cortex in Conditioning and Extinction in Chronically Relapsing Disorders*

Chair: Rita Goldstein

• *Factors that impact the functional reactivity of the fear extinction network across disorders*
  o Mohammed Milad
• *Retention of Extinction Learning for Monetary Reward in Cocaine Addiction: Role of the Amygdala and VMPFC*
Rita Goldstein

- Deficits in Ventromedial Prefrontal Cortex Group1 Metabotropic Glutamate Receptors Underpin Cognitive Dysfunction During Protracted Cocaine Withdrawal
  - Karen Szumlinski
- Role of ventral medial prefrontal cortex (mPFC) and its projections to accumbens shell on context-induced reinstatement of heroin seeking in rats
  - Jennifer Bossert
- Discussant: Gregory J. Quirk

Session 3

a4β2-Nicotinic Acetylcholine Receptors in Schizophrenia: Implications for Smoking Cessation and Therapeutics
Chair: A. Eden Evins

- In vivo evidence for β2*-nAChR upregulation in smokers as compared to nonsmokers with schizophrenia
  - Irina Esterlis
- Nicotinic CHRNA4 Exon 5 Genotype Predicts Clinical Outcome in Schizophrenia and Neuroleptic Drug Treatment-Response
  - Georg Winterer
- Examining the α4β2Nicotinic Partial Agnoist Varenicline on the Tobacco Abstinence Syndrome in Schizophrenia Versus Control Smokers
  - Victoria Wing
- Extended Duration Pharmacotherapy with Varenicline Prevents Relapse to Smoking in Adult Smokers with Schizophrenia
  - A. Eden Evins
- Discussant: Tony P. George

Session 4

New Directions for Optogenetics: Investigating Plasticity Mechanisms Underlying Psychiatric Disorders
Chair: Helen Simpson

- Brief Repeated Cortico-striatal Stimulation Leads to Persistent OCD-Relevant Behaviors
  - Susanne Ahmari
- Cortical Control of Brainstem Neuromodulatory Systems in Motivated Behavior
  - Melissa Warden
- Different Patterns of Stimulation in Projections from VTA to PFC Exert Distinct Effects on Behavioral Flexibility
  - Vikaas Sohal
- Molecular and Circuit Basis of Impaired Hippocampal-Prefrontal Synchrony in a Mouse Model of Schizophrenia Predisposition
  - Joshua Gordon
- Discussant: Karl Deisseroth
Session 5
Alterations of the Glutamate Cycle in Severe Mental Illness
Chair: Adrienne Lahti

- Glutamatergic abnormalities in medicated and unmedicated patients with schizophrenia
  o Adrienne Lahti
- Abnormalities of glutamate transporter expression in schizophrenia: Evidence for increased glutamate reuptake and altered subcellular partitioning of EAAT2 interacting proteins
  o Robert McCullumsmith
- Psychosis and cognition related to different brain glutamate pools in schizophrenia
  o Juan Bustillo
- Functional Implications of Altered In Vivo Glutamate and GABA Systems in Schizophrenia
  o Laura Rowland
- Discussant: Kelvin O. Lim

Session 6
Epigenetic Mechanisms in Neuropsychiatric Disorders
Chair: Paul Kenny

- MicroRNAs and Drug Addiction
  o Paul Kenny
- Global Transcriptome Analysis of Human Cerebrospinal Fluid
  o Claes Wahlestedt
- Insights into the Roles of the Methyl-DNA Binding Protein MeCP2 in Addictive-like Behaviors
  o Anne West
- MicroRNA 135 is Essential for Chronic Stress Resiliency, Antidepressant Efficacy and Intact Serotonergic Activity
  o Alon Chen
- Discussant: Eric Nestler

10:30 am - 4:30 pm  Poster Viewing
11:15 am - 12:30 pm  Business Meeting
  (ACNP Associate Members, Members and Fellows only)
12:00 pm – 2:00 pm  SOBP Program Committee Meeting
12:30 pm - 2:00 pm  Buffet Lunch
12:30 pm – 2:00 pm  Travel Award Luncheon (Awardees & Mentors Only)
3:00 pm – 5:30 pm  Mini-Panel Sessions
Session 1
Human Brain Evolution and Comparative Epigenomics
Chair: Schahram Akbarian
- Decoding the Molecular Evolution of Cognition
  - Genevieve Konopka
- Divergent Whole Genome Methylation Maps of Human and Chimpanzee Brains Reveal Epigenetic Basis of Human Regulatory Evolution and Disease Susceptibility
  - Soojin Yi
- Neuronal Epigenome Mapping in Human and Non-human Primate Prefrontal Cortex
  - Jogender Singh Tushir
- Discussant: Linda Porrino

Session 2
Intergenerational Transmission of Trauma – From Animal Models to Humans
Chair: Kerry Ressler
- Epigenetic Markers in the GR and FKBP5 Genes in Children of Holocaust Survivors
  - Rachel Yehuda
- Transgenerational Imprints on Structure and Function in the Mammalian Nervous System
  - Brian Dias
- Behavioral and Neural Mechanisms of the Intergenerational Transmission of Trauma
  - Jacek Debiec

3:00 pm - 5:30 pm       Panel Sessions

Session 1
Legal Damages: New Insights into Chronic Marijuana Effects on Human Brain Structure and Function
Chair: Steven Grant
- Impact of Chronic Marijuana Use on Reward and Control Brain Networks
  - Francesca Filbey
- Effect of Long-term Cannabis use on Axonal Fiber Connectivity
  - Andrew Zalesky
- Unmotivated? Signatures of blunted dopaminergic responsiveness in chronic marihuana abuse
  - Nora Volkow
- Multimodal MR Imaging in Adolescent MJ Users
  - Deborah Yurgelun-Todd

Session 2
Glutamate-dopamine interactions in nicotine and cocaine dependence: Biomarkers and Therapy Opportunities
Chair: Dean Wong
- In Vivo Imaging of Human mGluR5 and nAch receptors with PET: Dynamic Duo for Abuse Studies and Drug Occupancy?
  - Dean Wong
- Dopamine Activity and Reward Processing in Smokers Before and After Smoking Cessation: Combined [18F]FDOPA/fMRI Studies
Gerhard Grander
- Reduced mGluR5 Receptor Binding in Smokers and Ex-smokers Determined by [11C]ABP688 Positron Emission Tomography: Clinical and Scientific Relevance
  - Gregor Hasler
- Understanding Glutamate, Acetylcholine and Dopamine Interactions in Nicotine Dependence using Animal Models
  - Manoranjan D’Souza
- Discussant: Athina Markou

Session 3
Public-Private Repositioning Partnerships: A New Path to Achieve Target Validation and Proof of Concept for Novel CNS Indications
Chair: Linda Brady
- Drug Repositioning Through Open Innovation - An Industry Perspective
  - Donald Frail
- The MRC/AstraZeneca Mechanisms of Disease Compound Sharing Initiative
  - Christopher Watkins
- NCATS/NIH-Industry Pilot Program on Drug Repositioning
  - Christine Colvis
- Open Innovation and Mobile Health Technology to Improve and Accelerate Clinical Development
  - Tomasz Sablinski

Session 4
Multidimensional Data Integration and Causality: A Systems Approach for Unraveling the Molecular Architecture of Mental Disorders
Chair: Thomas Lehner
- Elucidating the Complexity of Psychiatric Disorders via the Integration of High-Dimensional, Multiscale Data
  - Eric Schadt
- Cis and trans data integration to find mechanisms causing psychiatric disorders
  - Edwin Van Den Oord
- The ENIGMA Consortium: Meta-Analyzing Neuroimaging and Genetic Data from 125 Institutions
  - Paul Thompson
- Computational analysis of complex human disorders
  - Andrey Rzhetsky
- Discussant: Steven Edward Hyman

Session 5
Early Stress and Emotion Dysregulation
Chair: Christian Schmahl
- Weakening Fear Memories as a Potential Treatment for Posttraumatic Stress Disorder
  - Karim Nader
- Effect of Direct Eye Contact in PTSD Related to Interpersonal Trauma: An fMRI Study of Activation of an Innate Alarm System
  - Ruth Lanius
Examining the genetic underpinnings of the amygdala habituation deficit in borderline personality disorder
  o M. Mercedes Peres-Rodriguez

Influence of Dissociation on Emotional Distraction in Borderline Personality Disorder
  o Annegret Krause-Utz

Discussant: Andreas Meyer-Lindenberg

Session 6
Neurobiological Regulation of Palatable Food Binging and Seeking
Chair: Jacqueline McGinty
  o Extended amygdala-hypothalamic inhibitory circuits regulate feeding
    o Garret Stuber
  o Cholinergic Control of Food Intake: Mechanisms Highjacked by Nicotine
    o Marina Picciotto
  o Serotonin Control in the Proclivity for High Impulsive Action and Binge Eating
    o Kathryn Cunningham
  o Neural Correlates of Craving, Cognitive Control and Reward Processing in Obesity and Binge-Eating Disorder
    o Marc Potenza
  Discussant: Jacqueline F. McGinty

5:30 pm - 7:30 pm  Poster Session III with Reception

Thursday, December 12, 2013

7:00 am – 8:00 am  ACNP/AsCNP/CINP/ECNP Meeting
8:00 am - 3:00 pm  Registration
8:00 am - 10:30 am  Panel Sessions

Session 1
Molecular Regulation and Clinical Applications of Phosphodiesterase 4, the Major Enzyme for Degrading cAMP
Chair: Robert Innis
  o PDE4 in Huntington’s Disease: Pathology of Cross-seeding of Huntingtin and Amyloidogenic DISC1
    o Koko Ishizuka
  o Control of Mood by Selective Potentiation of cAMP Signaling in Ventral Striatum
    o James Bibb
  o Structural and Pharmacological Studies of PDE4 Subtype Selective Allosteric Inhibitors
    o Mark Gurney
  o Binding of 11C-(R)-rolipram to Phosphodiesterase 4 is Downregulated in Major Depressive Disorder and Normalized with Antidepressant Treatment
    o Robert Innis
Session 2
Naltrexone Revisited: New Findings Beyond Mu, Beyond Dopamine and Beyond Addiction
Chair: Robert Swift
- **Naltrexone Effects on GABAergic Neuroactive Steroids: Associations to Subjective Responses and Pharmacogenetics**
  - Lara Ray
- **Neurocognitive Effects of Naltrexone**
  - Charlotte Boettiger
- **Naltrexone Pharmacotherapy for Adverse Metabolic Outcomes of Second Generation Antipsychotic Agents**
  - Igor Elman
- **Microglial Activation Alters Reward Circuitry in Chronic Pain States**
  - Catherine Cahill

Session 3
Understanding Neurodevelopmental Risk Factors leading to Anxiety and Depression to Inform Novel Early Interventions in Vulnerable Children
Chair: Ned Kalin
- **Neurobiology of Trauma and Infant Attachment: Short-term Benefits and Long-term Costs**
  - Regina Sullivan
- **Primate Anxious Temperament and Amygdala Metabolism are Environmentally Sensitive and Associated with Amygdalar Gene Expression**
  - Andrew Fox
- **Glucocorticoid Receptor Activation Induced Epigenetic Changes and Their Moderation by Genetic Variants as Potential Mediators of Risk and Resilience to Early Trauma-associated Psychiatric Disorders**
  - Elisabeth Binder
- **The Pervasive and Persistent Neurobiological Consequences of Child Abuse and Neglect; Clinical Implications**
  - Charles Nemeroff

Session 4
Brain on Fire: Inflammation in Neurological and Psychiatric Illness
Chair: Scott Russo
- **Pruning Developing CNS Synapses: An Active Role for Glia and Immune Molecules**
  - Beth Stevens
- **Monitoring neuroinflammation and demyelination using Magnetic Resonance Imaging in a preclinical setting**
  - Danielle Graham
- **Role of the peripheral immune system in stress-induced depressive behavior**
  - Georgia Hodes
- **Testing the Cytokine Hypothesis of Depression: Trials and Tribulations**
  - Andrew Miller
Session 5
Melatonin and its Receptors: Important Players in Major Depressive Disorder
Chair: Pierre Blier

- Melatonin-Mediated Potentiation of Physical Activity-Induced Neurogenesis in the Dentate Gyrus of the C3H/HeN Mouse.
  o Margarita Dubocovich
- Interactions between Melatonin and 5-HT Receptors to Enhance Monoaminergic Transmission in the Rat Brain
  o Pierre Blier
- Impact of Hippocampal Neurogenesis on Cognition and Mood
  o Rene Hen
- A Pilot, Placebo-Controlled Study of Buspirone Plus Melatonin in Major Depressive Disorder
  o Maurizio Fava

Session 6
Building a More Predictive Mouse: Humanized Mouse Models for Neuropsychiatric Disorders
Chair: Mark Geyer

- The Tryptophan Hydroxylase Arg439His Knockin (Tph2KI) Mouse: A Naturalistic Model of 5-HT Deficiency
  o Jacob Jacobsen
- Modeling the Contributions of Dopamine to ADHD via a Novel, Knock-In Mouse Model
  o Maureen Hahn
- Development and Characterization of Mice Humanized for the COMTval158met Polymorphism
  o Victoria Risbrough
- DISC1-Boymaw Fusion Gene May Contribute to Major Psychiatric Disorders in the Scottish Schizophrenia Family
  o Xianjin Zhou

Session 7
Broadening the Trajectories of Risk: Specific and Non-Specific Markers of Risk of Psychopathology
Chair: Kathleen Merikangas

- Comorbidity of Medical and Psychiatric Disorders in the Neurodevelopmental Genomics Cohort Study
  o Kathleen Merikangas
- The Study of Developmental Trajectories in Autism Spectrum Disorders; Lessons Learned
  o Peter Szatmari
- Clinical, Neurobiological and Circadian Correlates of the Onset and Course of Major Mood Disorders: From Childhood Risk to Adolescent-onset and Persistence into Adulthood
  o Ian Hickie
- Brain-Behavior Measures in Psychosis Spectrum Youths of the Philadelphia Neurodevelopmental Cohort
  o Raquel Gur

9:00 am - 12:00 pm  Council Meeting
Session 1
Behavioral, Endocrine, and Neural Plasticity Changes Reflecting Stress Associated with Mouse and Monkey Models of Heavy Alcohol Drinking
Chair: Howard Becker
- Behavioral and Neural Adaptations Linked to Stress Associated with a Mouse Model of Ethanol Dependence and Relapse Drinking
  - Howard Becker
- Behavioral and Endocrine Adaptations in a Monkey Model of Heavy Alcohol Drinking
  - Kathleen Grant
- Chronic Ethanol Exposure Increases Output from the Sensorimotor Striatum in Mouse and Monkey Models via Changes in Neuronal Excitability and Synaptic Transmission
  - David Lovinger
- Similar Dopamine System Adaptations in Mouse and Monkey Models of Excessive Alcohol Exposure
  - Sara Jones

Session 2
Experimental Therapeutics and Drug Development Targeting Inflammation in Developmental Disorders
Chair: Eric Hollander
- Gastrointestinal Symptoms in a Mouse Model of an Environmental Risk Factor for Autism and Schizophrenia
  - Paul Patterson
- Immune System as a Target for Therapeutic Intervention in Neurodevelopmental Disorders: Lessons from the Rett Syndrome
  - Jonathan Kipnis
- PET Imaging of Microglial Activation in Young Adults with Autism Spectrum Disorder
  - Kazuhiko Nakamura
- Translational Experimental Therapeutics of Inflammation and Fever in Autism Spectrum Disorder: Hot Tubs, Locus Coeruleus Modulation and Helminth Therapy
  - Eric Hollander

Session 3
Applying Animal and Human Models of Risk Avoidance and Impulsivity to Understanding Eating Disorders
Chair: Walter Kaye
- A Translational Assessment of Reward-Based Learning in Adolescents with Bulimia Nervosa
  - Rachel Marsh
- Harm avoidant behaviors and altered limbic and executive neural function in anorexia nervosa
  - Walter Kaye
- Striatal Dopamine D2 Receptor Modulation of Risky Decision Making
• **D1- and D2-like Dopamine Receptors, Impulsive Temperament and Corticostriatal Function as Related to Risky Decision-Making: Multimodal Imaging in Healthy Research Participants**
  o Edythe London

**Session 4**

*Novel Molecules and Mechanisms in Vulnerability and Resilience Throughout Life*

Chair: Marcelo Wood

• *miRNA programming in neurodevelopment: epigenetic targets in a dynamic landscape*
  o Tracy Bale

• **Epigenetic Pathways During Early Postnatal Life: How does a Neuron â€œKnowâ€• to Modulate its Epigenetic Machinery in response to Early-life Experience?**
  o Tallie Z. Baram

• **How neocortical Tet-mediated DNA hydroxymethylation regulates memory**
  o Timothy W. Bredy

• **Neuron-Specific Nucleosome Remodeling: A Missing Link in our Understanding of Epigenetic Mechanisms underlying Intellectual Disability Disorders.**
  o Marcelo Wood

**Session 5**

*Cognition, Biomarkers, and Longitudinal Outcomes in Geriatric Mood Disorders*

Chair: Helen Lavretsky

• **Longitudinal BDNF Levels in Both an Elderly Cohort and an Inflammatory Cytokine-Exposed Cohort: Risk for Cognitive Deficits**
  o Francis Lotrich

• **Late-life depression may increase risk of dementia but does not increase risk of developing Mild Cognitive Impairment**
  o Meryl Butters

• **Cognitive Control Network: Motivational Disturbances and Treatment Response of Late Life Depression**
  o George Alexopoulos

• **Combination of methylphenidate with citalopram is superior to either drug alone in improving clinical and cognitive outcomes in geriatric depression.**
  o Helen Lavretsky

**Session 6**

*The Insula Salience Network: Alterations in its Connectivity in Developmental, Anxiety, Mood and Personality Disorders*

Chair: Harold Koenigsberg

• **Insula - Conceptualizing Its Architecture, Function and Connectivity, with Applications to Understanding Large-scale Brain Networks in Psychopathology and Autism**
  o Vinod Menon

• **Insula-Amygdala Function and Connectivity in Trauma-Related Disorders: Relationship to Childhood Maltreatment**
  o Murray Stein
• Borderline Personality Disorder Patients Show Reduced Insula-Amygdala Functional Connectivity and Fail to Habituate When Viewing Repeated Negative Emotional Pictures
  o Harold Koenigsberg

• Elevated Posterior Insula ventral Striatal Connectivity to Reward in Youth with Bipolar Spectrum Disorders Relative to Youth with Other Behavioral and Emotional Dyregulation Disorders: A Potential Neural Marker of Heightened Reward-related Perceptual Salience in Bipolar Youth
  o Mary Phillips

Session 7
Strategies for the Development of Novel Therapies for Schizophrenia: From Clinic To Laboratory (And Back Again)'
Chair: Joel Kleinman
• Psychiatric GWAS Consortium triples schizophrenia GWAS sample-size to 31,000 cases and 37,000 controls
  o Stephen Ripke

• Integrating the genome, epigenome, and transcriptome in the human brain: accounting for biological and technical heterogeneity
  o Andrew Jaffe

• Understanding ZNF804A: allelic variation, alternative transcripts, brain development and schizophrenia
  o Thomas Hyde

• Applying lessons from DISC1 to convert gene discoveries into drug discoveries
  o Nicholas Brandon
Meeting Information
MEETING REGISTRATION AND HOTEL RESERVATIONS

Everyone who attends the Annual Meeting must be registered and must check in at the Meeting Registration Desk to receive meeting materials. People who are not registered or are registered as an Accompanying Person will not be allowed into any scientific sessions with the exception of the evening poster receptions. Attendees must wear name badges to be admitted into all sessions. The name badge policy will be strictly enforced. Meeting registration can be completed online per the instructions below. Should you need a printed form, please contact the Executive Office at 615-324-2360 or acnp@acnp.org

Attendees may not videotape, audiotape, or photograph (camera or camera phone) presentations at the ACNP Annual Meeting without prior permission from the panel chair.

REGISTRATION ONLINE

ACNP Member Registrations:
To access the registration site, members must login to the ACNP website, www.acnp.org, select “Annual Meeting” and click “Registration.”

Invited Guest Registrations:
Guests will receive a link to the registration site in their invitation letter sent via email.

You are encouraged to pre-register for the Meeting before Thursday, October 31, 2013. All Meeting registration fees will increase by $50.00 after this date.

In case of cancellation, please contact the ACNP Executive Office in writing no later than December 4, 2013, to receive a refund less a $30.00 processing fee.

CLIMATE AND DRESS

In December, average temperatures in Hollywood, Florida, range from a high of 74 degrees to a low of 65 degrees. The temperature of the meeting rooms may be somewhat warmer or cooler than you might expect. You are encouraged to wear layered outer clothing.

CHILDCARE

Childcare options will be available at the Westin Diplomat Resort and Spa for ACNP attendees with children one year of age to 12 years of age. More information about childcare times and costs are available on the ACNP website.
Pre-Register for the Annual Meeting by October 31st

WESTIN DIPLOMAT

The Westin Diplomat is the conference hotel. The last day for reservation acceptance at the discounted convention rates is Wednesday, October 31st. You are urged to make reservations as soon as possible, as availability is limited, and rooms will likely sell out before the deadline.

ROOM RATES AND INCLUSIONS: All rates are single/double occupancy per night, and are exclusive of applicable state and local taxes, which are currently 11%. Rollaway beds (only allowed in king bedded rooms) and cribs can be requested and are complimentary. All rooms have refrigerators. There is an additional $25 per night charge for each guest over two (2) adults sharing the same room. Children up to 21 are free. Maximum of four adults are allowed in a room. In-Room Wireless High Speed Internet Access USD 6.00 per day. Complimentary internet access is available in the hotel lobby.

The Westin Diplomat’s guest rooms, common areas, and transportation services are in compliance with the public accommodation requirements of the Americans with Disabilities Act. These facilities will be accessible to and usable by individuals with disabilities who attend and participate in the Annual Meeting. If you have special needs because of a physical disability, please contact the ACNP Executive Office at 615-324-2360.

THE WESTIN DIPLOMAT ROOM GUARANTEE: All ACNP guests will be required to provide credit card information during the online hotel reservation process to guarantee your reservation. This card will only be charged if you fail to follow the CHANGE/CANCELLATION Policy below.

PRE/POST MEETING STAYS: ACNP discounted group rates are available three days before and three days after meeting dates; space is limited and based on availability. If your preferred early arrival or late departure dates are not available, you will be waitlisted and notified should they become available. Note: As pre/post space is limited, we recommend that you make air travel plans after you receive your hotel confirmation.

CHANGING YOUR RESERVATION: Please contact the Westin Diplomat In-House Reservations at (954) 602-8700 Monday–Friday 8:00am-6:00pm Eastern.

CHANGES IN YOUR ARRIVAL DATE: Guests staying at the Westin Diplomat may make changes in their arrival date without penalty up until 72 hours prior to scheduled arrival. Should you change your arrival date to shorten your stay within 72 hours of your arrival date, your one night deposit will be forfeited.

CHANGES IN YOUR DEPARTURE DATE: Guests staying at the Westin Diplomat may change their departure date up until the time of hotel check-in. You will be asked to re-confirm your date of departure upon hotel check-in. Should you make a change in your departure date to shorten your stay after check in, your one night deposit will be forfeited.

HOTEL CANCELLATION POLICY: Guests staying at the Westin Diplomat may cancel your room without penalty up until 72 hours prior to scheduled arrival date. Should you cancel within 72 hours of your arrival date, a one night deposit will be charged. Failure to arrive at the hotel on your scheduled arrival date will result in the loss of your one night charge, and your room will be released for general sale.
SMOKE FREE: The Westin Diplomat Resort & Spa announces the introduction of the 'Breathe Westin' program. In response to guest requests, every guest room and all indoor areas are now designated as 'smoke free'. To assist guests who smoke in this transition, the Westin has additional seating and ash bins on the resort grounds. Note: To ensure a refreshing experience upon each return, Westin Hotels & Resorts enforces its smoke free policy in guest rooms and balconies with a $200 cleaning fee for violations.

OTHER HOTELS

Reservations are also available at the Crowne Plaza Hollywood Beach and the Hollywood Beach Marriott. Access to the ACNP room blocks is provided in your registration confirmation email.

AIR TRAVEL AND GROUND

TRANSPORTATION

Air Travel: The closest airports to the ACNP headquarters hotel are the Hollywood/Fort Lauderdale International Airport and the Miami International Airport. ACNP has secured discounted airfares with American and Delta Airlines for travel to the ACNP 52nd Annual Meeting in Hollywood, Florida. The ACNP has partnered with Caldwell Travel, Inc. for airline and car rental reservations. Please contact Lead Travel Consultants, Javonna Williams, javonnaw@travelcaldwell.com, or Sue Shapiro sues@travelcaldwell.com at 615-277-9067, toll-free 800-229-3344, between the hours of 9:00a.m. and 5:30p.m. CST, Monday – Friday. (You may reach other fine travel consultants at Caldwell’s Headquarters Office between operational hours of 7:30a.m. and 5:30p.m. at 615-327-2720.)

Ground Transportation:
Rental Cars:
Hertz and Avis are offering special discounts to all ACNP attendees. To reserve your car rental call Caldwell Travel at 615-277-9067 or 800-229-3344 or email acnp@travelcaldwell.com.

Ground Transportation:
By Taxi
Follow signs in either airport for ground transportation and taxi service. Fares range from $25 to $35 one way to/from Fort Lauderdale/Hollywood International Airport and $60 to $80 one way to/from Miami International.

Shared Ride - Shuttle Service: Go Airport Shuttle and Executive Car Service provides airport/hotel shuttle service from the Ft. Lauderdale Airport to the Westin Diplomat. One way fare is $13 (includes gratuity). No reservations are needed for the transfer from the airport to the hotel; meet the shuttle at the airport lower level curbside (maximum 30-minute wait for a shuttle, but most shuttles leave within ten minutes). Shuttles stop at multiple hotels (up to 45 minutes) along the way. For return trip from the Westin Diplomat to the Ft. Lauderdale airport, a reservation is required with minimum 24-hour notice. One way fare is $13 (includes gratuity). Shuttle will make multiple stops on the return trip as well. To make a return reservation, call 954-561-8888 or 800-244-8252, or www.go-airportshuttle.com.

Private Transfer: Go Airport Shuttle and Executive Car Service provides private airport/hotel transfers from the Ft. Lauderdale Airport to the Westin Diplomat.

Arrival Transfer from Ft. Lauderdale Airport to Westin: No reservations are needed for this transfer from the airport to the hotel; request a private sedan outside of baggage claim. Estimated 5-10 minute wait for a sedan. One way fare is $45 (plus gratuity).
**Arrival Transfer with Meet and Greet Service:** You may arrange for a driver to meet you at baggage claim with a sign bearing your name, assist you with your luggage, and transfer you to the Westin for a one way charge of $63.25 (plus gratuity). Reserve by calling 954-561-8888 or 800-344-8252 or online at www.go-airportshuttle.com.

**Return Transfer from Westin Diplomat to Ft. Lauderdale Airport:** For a return transfer from the Westin to the Ft. Lauderdale airport via a private sedan, a reservation is required with minimum 24-hour notice. One way fare is $45 (plus gratuity). To make a reservation, call 954-561-8888 or 800-244-8252, or www.go-airportshuttle.com.

**HOTEL PARKING**

To make parking convenient valet and self-parking are available 24 hours a day. Self-parking is located at a multi-level facility connected through a covered skywalk. Parking rates are: valet parking at $24 per day and self-parking across the street at $20 per day with in/out privileges.
INFORMATION ABOUT CME CREDIT

The 2013 ACNP Annual Meeting is jointly sponsored by the Vanderbilt University School of Medicine and the ACNP. This activity has been planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for CME (ACCME) through the joint sponsorship of Vanderbilt University School of Medicine and the ACNP.

Vanderbilt University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vanderbilt University School of Medicine designates this live activity for a maximum of 36.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There will be a $40.00 charge for scientific registrants to obtain CME credits. CME instructions will be available at the meeting registration desk and on the ACNP website (www.acnp.org).

It is the policy of Vanderbilt University School of Medicine and the ACNP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Program Overview/Statement of Need

The Annual Meeting of the American College of Neuropsychopharmacology is designed to meet the educational needs of ACNP members and invited non-member colleagues. Current data suggests that in any given year more than 20% of the U.S. adult population suffers from a diagnosable mental disorder. Four of the ten leading causes of disability in the U.S. are psychiatric disorders, including schizophrenia, depression, bipolar disorder, and obsessive-compulsive disorder. ACNP members have been among the leaders in identifying underlying mechanisms for these disorders and developing new treatment strategies. The desired results for the meeting are that ACNP members and their invited guests learn of the latest developments in preclinical and clinical research being performed by their colleagues and world experts in order to 1) enhance understanding of the neurobiological bases of current best practice approaches, 2) enhance understanding of neurobiological and clinical science underpinnings in development of novel therapeutic strategies, particularly for treatment-resistant forms of illness, and 3) lead to improvements in study designs for proposed clinical and basic studies.

Target Audience

The target audience includes members of the American College of Neuropsychopharmacology and invited experts. The audience includes physicians, psychologists, and basic neuroscientists from across the United States as well as Europe and Asia. The physicians include a number of specialties, with psychiatrists representing the majority of attendees, and neurologists next most common. Psychologists include clinical psychologists and neuropsychologists.
Learning Objectives:

After participating in this CME activity, participants should be able to:

- Describe and discuss how the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area impact your current or potential future research projects.

- Describe and discuss how you will change or modify a current approach or strategy in your current or potential future research projects based on what you learned from the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area.

- Describe and discuss how recent progress in identifying genetic variations that are risk factors for the development of psychiatric disorders affect your current or potential future research projects.

Americans with Disabilities Act

It is the policy of Vanderbilt University School of Medicine not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-324-2360 or send an email to acnp@acnp.org.

Register Online at

www.acnp.org